Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that affec...

Full description

Bibliographic Details
Main Authors:	Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-02-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231152843

Similar Items

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer
by: Komal Jhaveri, et al.
Published: (2023-12-01)

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
by: Hope S. Rugo, et al.
Published: (2022-11-01)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
by: Michele Iuliani, et al.
Published: (2022-02-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
by: Chunfang Hao, et al.
Published: (2023-01-01)

P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
by: S. Johnston, et al.
Published: (2023-03-01)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
by: Qiran Wei, et al.
Published: (2023-11-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
by: Laura M. Spring, et al.
Published: (2021-08-01)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer
by: Dennis J. Slamon, et al.
Published: (2023-05-01)

P084 Socioeconomic Outcomes With Ribociclib in Patients With HR+, HER2– Advanced Breast Cancer (ABC) in UK Real-world Settings
by: P. Hall, et al.
Published: (2023-03-01)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
by: P. Neven, et al.
Published: (2023-08-01)

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
by: I. V. Kolyadina
Published: (2021-09-01)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
by: Mónica Cejuela, et al.
Published: (2023-05-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
by: Anna Maria Buehler, et al.
Published: (2022-12-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study
by: Nour Hisham Al-Ziftawi, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
by: Alison Davie, et al.
Published: (2023-09-01)

Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
by: Alistair Ring, et al.
Published: (2023-09-01)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
by: Shani Paluch-Shimon, et al.
Published: (2023-02-01)

Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer
by: A. Yu. Goryainova, et al.
Published: (2022-06-01)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Published: (2023-09-01)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
by: Javier Salvador Bofill, et al.
Published: (2022-12-01)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
by: Stephen Johnston, et al.
Published: (2021-06-01)

Clinical aspects of the use of ribociclib
by: A. A. Markovich, et al.
Published: (2020-07-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
by: Mirko Fillbrunn, et al.
Published: (2022-09-01)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
by: Hope S. Rugo, et al.
Published: (2022-10-01)

Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
by: N. S. Prizova, et al.
Published: (2022-06-01)

Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer
by: N. S. Besova
Published: (2020-07-01)

Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
by: Hiroji Iwata, et al.
Published: (2023-09-01)

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
by: Sharaf B, et al.
Published: (2023-07-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
by: Nicoletta Staropoli, et al.
Published: (2022-09-01)

896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance
by: Sara M Tolaney, et al.
Published: (2023-11-01)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
by: Florian Carneiro, et al.
Published: (2023-01-01)

Ribociclib-induced liver injury: a case report
by: Sofia Schaeffer, et al.
Published: (2023-12-01)